PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18289119-3	2008	Two promising classes of PAS-targeting agents are inhibitors of the serine protease activity of urokinase plasminogen activator (uPA) and antagonists of the interaction of uPA with its cell surface receptor (uPAR).	Aminosalicylic Acid	25-28	plasminogen activator, urokinase	Homo sapiens	96-127	
18289119-3	2008	Two promising classes of PAS-targeting agents are inhibitors of the serine protease activity of urokinase plasminogen activator (uPA) and antagonists of the interaction of uPA with its cell surface receptor (uPAR).	Aminosalicylic Acid	25-28	plasminogen activator, urokinase	Homo sapiens	129-132	
18289119-3	2008	Two promising classes of PAS-targeting agents are inhibitors of the serine protease activity of urokinase plasminogen activator (uPA) and antagonists of the interaction of uPA with its cell surface receptor (uPAR).	Aminosalicylic Acid	25-28	plasminogen activator, urokinase	Homo sapiens	172-175	
2129127-7	1990	The blood clot lysis caused by the clot-bound PAs was investigated using the [125I]fibrin-containing blood clots pretreated with t-PA or u-PA.	Aminosalicylic Acid	46-49	plasminogen activator, urokinase	Homo sapiens	137-141	
34276988-6	2021	While the primary activation pathway for PAS occurs through the urokinase plasminogen activator (uPA), which is highly expressed by endothelial cells, its function is not limited to enabling revascularisation.	Aminosalicylic Acid	41-44	plasminogen activator, urokinase	Homo sapiens	64-95	
34276988-6	2021	While the primary activation pathway for PAS occurs through the urokinase plasminogen activator (uPA), which is highly expressed by endothelial cells, its function is not limited to enabling revascularisation.	Aminosalicylic Acid	41-44	plasminogen activator, urokinase	Homo sapiens	97-100